Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers
Open Access
- 1 December 2012
- journal article
- research article
- Published by Informa UK Limited in Human Vaccines & Immunotherapeutics
- Vol. 8 (12), 1892-1903
- https://doi.org/10.4161/hv.22166
Abstract
Effective vaccines offering broad protection to toddlers, who are at high risk for invasive meningococcal disease, are needed. Here, the immunogenicity, safety and antibody persistence of the tetravalent meningococcal ACWY tetanus toxoid conjugate vaccine (MenACWY-TT) were evaluated in toddlers. Healthy participants aged 12 to 23 mo (n = 304) were randomized (3:1) to receive one dose of MenACWY-TT or a monovalent meningococcal serogroup C conjugate vaccine (MenC-CRM197). Serum bactericidal activity was evaluated with assays using rabbit (rSBA) and human (hSBA) complement up to three years post-vaccination. MenACWY-TT was demonstrated to be non-inferior to MenC-CRM197 in terms of immunogenicity to serogroup C, and the pre-specified immunogenicity criteria for serogroups A, W-135 and Y were met. Exploratory analyses suggested that rSBA geometric mean titers (GMTs), hSBA GMTs and proportions of toddlers with rSBA titers ≥ 1:128 and hSBA titers ≥ 1:4 and ≥ 1:8 were higher for all serogroups at one month post-...Keywords
This publication has 57 references indexed in Scilit:
- Emergence of Epidemic Neisseria meningitidis Serogroup X Meningitis in Togo and Burkina FasoPLOS ONE, 2011
- Measurement of Functional Anti-Meningococcal Serogroup A Activity Using Strain 3125 as the Target Strain for Serum Bactericidal AssayClinical and Vaccine Immunology, 2011
- Long-term Sequelae of Childhood Bacterial MeningitisThe Pediatric Infectious Disease Journal, 2011
- Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescentsHuman Vaccines, 2010
- Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd ImmunityClinical and Vaccine Immunology, 2010
- Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C VaccineClinical and Vaccine Immunology, 2010
- Ex Vivo Model of Meningococcal Bacteremia Using Human Blood for Measuring Vaccine-Induced Serum Passive Protective ActivityClinical and Vaccine Immunology, 2009
- Global epidemiology of meningococcal diseaseVaccine, 2009
- Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit SeraInfection and Immunity, 2009
- Complications and sequelae of meningococcalinfections in childrenThe Journal of Pediatrics, 1981